GSK plc, a London-headquartered multinational pharmaceutical and biotechnology company, is investing up to $800 million in Pennsylvania to increase its R&D and manufacturing footprint at its existing facility in Lancaster County, Pa.
“Pennsylvania is a leader in life sciences and GSK’s decision to make its largest single investment ever in manufacturing in the United States right here in the commonwealth is further proof that we are the best state in the nation for business growth and economic development,” Pennsylvania Gov. Josh Shapiro said on Oct. 24.
The state is supporting GSK’s expansion with a $21 million investment, which will create at least 200 new high-paying jobs, Shapiro said.
“Our commonwealth offers the skilled workforce, market access, and innovation infrastructure that biotech and life sciences companies need to thrive,” the governor said.
GSK plans to expand its existing facility at 325 North Bridge Street in Marietta, Pa., with new facilities where vaccines and medicines will be manufactured. Currently, one in four Americans are administered a vaccine supplied from this location, which will be doubled in size and capacity.